Patient Card

This card has been reviewed and approved by The Saudi Food and Drug Authority (SFDA), Version 3, May 2026.

Patient Card CARVYKTI®
(ciltacabtagene autoleucel)

Please fill in your information and keep this card with you at all times. In the event of emergency call the number provided on your card and go to the CAR-T treatment center or local hospital right away. Show this card to any healthcare professional who sees you.

PATIENT'S NAME:

_____

Emergency Contact

PATIENT CARER'S NAME:

_____

PATIENT CARER'S PHONE NUMBER:

_____

This card has been reviewed and approved by The Saudi Food and Drug Authority (SFDA), Version 3, May 2026.

Primary CAR-T Healthcare Professional

HEALTHCARE PROFESSIONAL'S NAME:

_____

HEALTHCARE PROFESSIONAL'S PHONE NUMBER:

_____

CAR-T CENTRE ADDRESS:

_____

CAR-T CENTRE PHONE NUMBER:

_____

This card has been reviewed and approved by The Saudi Food and Drug Authority (SFDA), Version 3, May 2026.

Important Information for Patients

Carry this card with you at all times. Show it to any doctor who sees you and when you go to the hospital. Tell any healthcare professional who sees you that you have been treated with ciltacabtagene autoleucel.

Plan to stay near the hospital where you were treated for at least 4 weeks after you have ciltacabtagene autoleucel.

Do not drive or use tools or machines until at least 8 weeks after ciltacabtagene autoleucel infusion. Refer to the Patient Information Leaflet for more information.

This card has been reviewed and approved by The Saudi Food and Drug Authority (SFDA), Version 3, May 2026.

If you experience any newly occurring symptoms, especially any of the symptoms listed on this card, please immediately notify your physician, your treating healthcare professional, or any healthcare professional available.

Ciltacabtagene autoleucel can cause serious side effects in different parts of your body. These symptoms can be life-threatening and need to be addressed immediately.

Symptoms that appear mild may quickly worsen.

Symptoms may be delayed and may occur weeks after your infusion.

This card has been reviewed and approved by The Saudi Food and Drug Authority (SFDA), Version 3, May 2026.

Call your treating healthcare professional straight away if you have any of these symptoms:

Cytokine release syndrome (CRS)

Fever (38°C or higher)

Chills

Fast heart beat

Difficulty breathing

Feeling dizzy or lightheaded

Neurologic toxicity

Feeling confused

Feeling less alert, disorientated, anxious or having memory loss

Having difficulty speaking or slurred speech

Slower movements or changes in handwriting

This card has been reviewed and approved by The Saudi Food and Drug Authority (SFDA), Version 3, May 2026.

Information for Healthcare Team to Fill in

Please give this card to your CAR-T healthcare team to fill in the information and return to you.

ON (DATE) _____

This patient received ciltacabtagene autoleucel, which is a chimeric antigen receptor T cell therapy (CAR-T cell therapy) for multiple myeloma.

(BATCH ID) _____

This card has been reviewed and approved by The Saudi Food and Drug Authority (SFDA), Version 3, May 2026.

Important Information for Healthcare Professionals

This patient has received an engineered autologous T-cell immunotherapy product that can lead to severe CRS and neurologic toxicity. CRS may involve any organ system. Assess the patient for signs and symptoms of CRS and neurologic toxicity.

See Summary of Product Characteristics for full details.

Before providing any treatment, call the primary healthcare professional at the number on the front of the card. This patient should not donate blood, organs, tissues or cells for transplantation.

This card has been reviewed and approved by The Saudi Food and Drug Authority (SFDA), Version 3, May 2026.

Adverse events reporting guidance:
The National Pharmacovigilance Centre (NPC), SFDA:
Email: npc.drug@sfda.gov.sa
Telephone: 19999
Online: http://ade.sfda.gov.sa

For full prescribing information, please refer to the datasheet or contact **Johnson & Johnson Trading Limited (Riyadh)**

Address: Prince Muhammed Bin Abdulaziz Rd, Tower B, Level 30, Olaya towers.
Office Tel 00966-11-4339133
Postal address: P.O. Box 65305 Riyadh 11556, Saudi Arabia
To report Adverse Events/Product Complaint or any Medical Information Inquiries, please contact us at:
Email: GCC-PV2@its.jnj.com
Hotline: 00966540015811

This card has been reviewed and approved by The Saudi Food and Drug Authority (SFDA), Version 3, May 2026.